Background: The Janus kinase-2 (JAK-2) V617F mutation has been recently reported in patients with myeloproliferative disorders (MPD), which is believed to ...跳至主導覽跳至搜尋跳過主要內容PrevalenceoftheJAK2-V617FmutationinTaiwanesepatientswithchronicmyeloproliferativedisordersC.H.Lieu,H.S.Wu,Y.C.Hon,W.H.Tsai,C.F.Yang,C.C.Wang,Y.C.Lin,C.H.Shih,H.C.Hsu呼吸治療學系臺北醫學大學附設醫院胸腔內科臺北醫學大學胸腔醫學研究中心研究成果:雜誌貢獻›文章›同行評審10引文斯高帕斯（Scopus）總覽指紋摘要Background:TheJanuskinase-2(JAK-2)V617Fmutationhasbeenrecentlyreportedinpatientswithmyeloproliferativedisorders(MPD),whichisbelievedtounderliegrowthfactorhypersensitivitydisplayedbyhaematopoieticprogenitorsinthesedisorders.However,itsfrequencyhasbeenrarelydeterminedinTaiwanesepatients.Methods:ThefrequencyofJAK2-V617Fmutationinpatientswithpolycythaemiavera,essentialthrombocythaemiaandidiopathicmyelofibrosis(IMF)wasdeterminedintheDNAfromtheperipheralbloodleucocytesof108patientsbygenomicpolymerasechainreactionandrestrictionenzyme-basedassay.Results:TheJAK2-V617Fmutationcouldbedetectedin28of33polycythaemiaverapatients(85%),29of49essentialthrombocythaemiapatients(59%)and2of6IMFpatients(33%),butwasnotdetectedin11patientswithmyelodysplasticsyndromeoranother10withotherhaematologicaldiseases.ThepresenceoftheJAK2mutationwasassociatedwithspecificMPDdiseasesubtypes(P=0.007),longerdiseaseduration(P=0.005),splenomegaly(P=0.019),ahigherwhitebloodcellcount(P=0.002)andahigherhaemoglobinlevel(P=0.036).However,theoverallriskofthrombosisorbleedingwasnotaffectedbythepresenceoftheJAK2mutation(32vs17%;P=0.22).Conclusion:TheJAK2-V617FmutationcanbefrequentlydetectedintheTaiwanesepatientswithMPDdisordersandthereforeshouldbeincorporatedintotheinitialevaluationofpatientssuspectedofMPD.原文英語頁（從-到）422-426頁數5期刊InternalMedicineJournal卷38發行號6ADOIshttps://doi.org/10.1111/j.1445-5994.2007.01589.x出版狀態已發佈-六月2008ASJCScopussubjectareasInternalMedicine存取文件10.1111/j.1445-5994.2007.01589.x其它文件與鏈接LinktopublicationinScopusLinktocitationlistinScopusMyeloproliferativeDisordersMedicine&LifeSciencesMutationMedi